Is there risk of stroke with aflibercept?

Ophthalmology

Volumn 121, Issue 1, 2014, Pages

  Beaumont, Paul E ^a   Petocz, Peter ^b   Kang, Hyong K ^a  

^a Retina and Vitreous Centre   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; PLASMINOGEN ACTIVATOR INHIBITOR; RANIBIZUMAB; VASCULOTROPIN;

CEREBROVASCULAR ACCIDENT; GENETIC TRANSCRIPTION; HUMAN; LETTER; PRIORITY JOURNAL;

FEMALE; HUMANS; MALE; RECOMBINANT FUSION PROTEINS; WET MACULAR DEGENERATION;

EID: 84891626777     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.09.020     Document Type: Letter

References (5)

1. J.S. Heier, D.M. Brown, and V. Chong et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
2. European Medicines Agency. 2012 Assessment Report: Eylea (Aflibercept). Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002392/WC500135744.pdf. Accessed December 10, 2012.
3. M.C. Gillies, and T.Y. Wong Ranibizumab for neovascular age related macular degeneration N Engl J Med 356 2007 748 749
4. U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Ranibizumab versus bevacizumab to treat age-related macular degeneration: one-year findings from the IVAN randomised trial Ophthalmology 119 2012 1399 1411
5. T. Hoekstra, J.M. Geleijnse, and C. Kluft et al. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly Stroke 34 2003 2822 2828